Every Form 4 that Tvardi Therapeutics, Inc. (TVRD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TVRD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVRD filings page.
Tvardi Therapeutics, Inc. director Susan Shiff, Ph.D. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036. 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, subject to her continuous service. Following this grant, she holds 6,000 stock options directly.
Tvardi Therapeutics, Inc. director Cynthia Smith reported receiving a grant of stock options as equity compensation. The award covers 6,000 options to buy Tvardi common stock at an exercise price of $2.78 per share, expiring on June 8, 2036.
All 6,000 underlying shares vest in a single tranche on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided she remains in continuous service through that vesting date. Following this grant, she holds 6,000 derivative securities directly.
Tvardi Therapeutics director Sujal Shah received a stock option grant for 6,000 shares of common stock. The option has an exercise price of $2.78 per share and expires on June 8, 2036. All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, assuming he remains in continuous service.
Tvardi Therapeutics, Inc. director Hall Wallace Jr. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036.
All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, as long as Wallace continues in service through that date. This is a compensation-related award rather than an open-market purchase or sale.
Tvardi Therapeutics, Inc. director Michael S. Wyzga received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.7800 per share and expire on June 8, 2036. Following this grant, he holds 6,000 derivative securities directly.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided he continues serving through the vesting date. This is a compensation-related award rather than an open-market purchase.
Tvardi Therapeutics, Inc. reported that Principal Accounting Officer Stephen Paul O'Brien received an employee stock option award on January 29, 2026. The option gives him the right to buy 15,000 shares of common stock at an exercise price of $3.90 per share.
The option vests in equal monthly installments over 48 months starting January 29, 2026, so vesting continues as long as he remains in continuous service with the company. The option expires on January 29, 2036, and all 15,000 derivative securities are reported as directly owned after this grant.
Tvardi Therapeutics, Inc. reported that its Chief Financial Officer, Avi Daniel Conn, received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share, expiring January 29, 2036.
The options vest in equal monthly installments over 48 months, starting January 29, 2026, as long as Conn remains in continuous service through each vesting date. Following this grant, Conn holds 45,000 derivative securities directly.
Tvardi Therapeutics, Inc. reported that its Chief Medical Officer, Kauh John Saewook, M.D., received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share.
These options vest in equal monthly installments over 48 months starting January 29, 2026, as long as the executive remains in continuous service. Following this grant, the reporting person beneficially owns 45,000 derivative securities, all held as direct ownership.
Tvardi Therapeutics, Inc. reported an insider equity award for its chief executive officer and director, Alibhai Imran Nizamudin. On January 29, 2026, he received an employee stock option covering 115,000 shares of common stock at an exercise price of $3.9 per share.
These options vest in equal monthly installments over 48 months starting January 29, 2026, contingent on his continued service with the company. Following this grant, he beneficially owns 115,000 derivative securities directly through this option award.
Tvardi Therapeutics, Inc. reported that one of its officers, serving as Principal Accounting Officer, received an employee stock option grant. The option allows the officer to buy 4,000 shares of common stock at an exercise price of $4.2 per share, with a stated expiration date of December 16, 2035.
According to the vesting terms, 25% of the option shares will vest on December 16, 2026. The remaining shares will then vest in equal monthly installments over the following 36 months, as long as the officer continues to provide service through each vesting date. After this grant, the officer beneficially owns 4,000 derivative securities directly.
Tvardi Therapeutics, Inc. Chief Medical Officer, filing as a single reporting person, reported a new grant of employee stock options. On 12/16/2025, the officer received an option to purchase 17,500 shares of common stock at an exercise price of $4.2 per share, held as direct ownership. The option expires on 12/16/2035.
According to the vesting terms, 25% of the shares subject to the option will vest on December 16, 2026. The remaining 75% will then vest in equal monthly installments over the following 36 months, conditioned on the officer’s continuous service through each vesting date.
Tvardi Therapeutics, Inc. reported an insider equity award to its Chief Financial Officer on a Form 4. The CFO received an employee stock option giving the right to buy 17,500 shares of common stock at an exercise price of $4.2 per share, granted on 12/16/2025 and expiring on 12/16/2035.
According to the vesting terms, 25% of the option shares vest on December 16, 2026. The remaining shares vest in equal monthly installments over the following 36 months, as long as the executive remains in continuous service through each vesting date. The transaction is reported as directly owned by the CFO and reflects standard stock-based compensation rather than an open-market stock purchase or sale.
Tvardi Therapeutics, Inc. reported that its Chief Executive Officer and director received an employee stock option grant. On December 16, 2025, the insider was granted an option to purchase 47,500 shares of common stock at an exercise price of $4.2 per share, with an expiration date of December 16, 2035.
According to the vesting schedule, 25% of the shares underlying the option will vest on December 16, 2026. The remaining shares will then vest in equal monthly installments over the following 36 months, conditioned on the reporting person’s continuous service with the company through each vesting date.